You are here: Home » PTI Stories » National » News
Business Standard

Orchid Pharma gets EIR from USFDA for Tamil Nadu plant

Press Trust of India  |  New Delhi 

Drug firm Orchid Pharma today said the US health regulator has issued establishment inspection report (EIR) for its manufacturing facility in

The company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) based on the successful inspection of the formulation manufacturing facility at Irungattukottai, Orchid Pharma said in a filing to



"The facility was inspected by the USFDA in December 2016," it added.

Upon completion of an inspection by FDA, an EIR is issued which details inspectional findings.

of Orchid Pharma today closed at Rs 36.55 per scrip on BSE, up 5.33 per cent from its previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Orchid Pharma gets EIR from USFDA for Tamil Nadu plant

Drug firm Orchid Pharma today said the US health regulator has issued establishment inspection report (EIR) for its manufacturing facility in Tamil Nadu. The company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) based on the successful inspection of the formulation manufacturing facility at Irungattukottai, Orchid Pharma said in a filing to BSE. "The facility was inspected by the USFDA in December 2016," it added. Upon completion of an inspection by FDA, an EIR is issued which details inspectional findings. Shares of Orchid Pharma today closed at Rs 36.55 per scrip on BSE, up 5.33 per cent from its previous close. Drug firm Orchid Pharma today said the US health regulator has issued establishment inspection report (EIR) for its manufacturing facility in

The company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) based on the successful inspection of the formulation manufacturing facility at Irungattukottai, Orchid Pharma said in a filing to

"The facility was inspected by the USFDA in December 2016," it added.

Upon completion of an inspection by FDA, an EIR is issued which details inspectional findings.

of Orchid Pharma today closed at Rs 36.55 per scrip on BSE, up 5.33 per cent from its previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Orchid Pharma gets EIR from USFDA for Tamil Nadu plant

Drug firm Orchid Pharma today said the US health regulator has issued establishment inspection report (EIR) for its manufacturing facility in

The company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) based on the successful inspection of the formulation manufacturing facility at Irungattukottai, Orchid Pharma said in a filing to

"The facility was inspected by the USFDA in December 2016," it added.

Upon completion of an inspection by FDA, an EIR is issued which details inspectional findings.

of Orchid Pharma today closed at Rs 36.55 per scrip on BSE, up 5.33 per cent from its previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22